Truist Securities Maintains Hold on Corcept Therapeutics, Raises Price Target to $29
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Gregory Fraser has maintained a 'Hold' rating on Corcept Therapeutics (NASDAQ:CORT) and raised the price target from $26 to $29.
August 04, 2023 | 1:46 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Corcept Therapeutics' price target has been raised from $26 to $29 by Truist Securities, while maintaining a 'Hold' rating.
The news is directly about Corcept Therapeutics. The raised price target indicates a positive outlook, but the 'Hold' rating suggests that the stock is fairly valued at the moment. This could lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100